360 related articles for article (PubMed ID: 23394580)
41. The Profile of MicroRNA Expression and Potential Role in the Regulation of Drug-Resistant Genes in Cisplatin- and Paclitaxel-Resistant Ovarian Cancer Cell Lines.
Kazmierczak D; Jopek K; Sterzynska K; Nowicki M; Rucinski M; Januchowski R
Int J Mol Sci; 2022 Jan; 23(1):. PubMed ID: 35008952
[TBL] [Abstract][Full Text] [Related]
42. A miR-200b/200c/429-binding site polymorphism in the 3' untranslated region of the AP-2α gene is associated with cisplatin resistance.
Wu Y; Xiao Y; Ding X; Zhuo Y; Ren P; Zhou C; Zhou J
PLoS One; 2011; 6(12):e29043. PubMed ID: 22194984
[TBL] [Abstract][Full Text] [Related]
43. Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone.
Roque DM; Bellone S; Buza N; Romani C; Cocco E; Bignotti E; Ravaggi A; Rutherford TJ; Schwartz PE; Pecorelli S; Santin AD
Am J Obstet Gynecol; 2013 Jul; 209(1):62.e1-9. PubMed ID: 23583215
[TBL] [Abstract][Full Text] [Related]
44. The interplay of HuR and miR-3134 in regulation of AU rich transcriptome.
Sharma S; Verma S; Vasudevan M; Samanta S; Thakur JK; Kulshreshtha R
RNA Biol; 2013 Aug; 10(8):1283-90. PubMed ID: 23823647
[TBL] [Abstract][Full Text] [Related]
45. A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer.
Ratner ES; Keane FK; Lindner R; Tassi RA; Paranjape T; Glasgow M; Nallur S; Deng Y; Lu L; Steele L; Sand S; Muller RU; Bignotti E; Bellone S; Boeke M; Yao X; Pecorelli S; Ravaggi A; Katsaros D; Zelterman D; Cristea MC; Yu H; Rutherford TJ; Weitzel JN; Neuhausen SL; Schwartz PE; Slack FJ; Santin AD; Weidhaas JB
Oncogene; 2012 Oct; 31(42):4559-66. PubMed ID: 22139083
[TBL] [Abstract][Full Text] [Related]
46. MicroRNA-16 modulates HuR regulation of cyclin E1 in breast cancer cells.
Guo X; Connick MC; Vanderhoof J; Ishak MA; Hartley RS
Int J Mol Sci; 2015 Mar; 16(4):7112-32. PubMed ID: 25830480
[TBL] [Abstract][Full Text] [Related]
47. Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers.
Liu G; Yang D; Rupaimoole R; Pecot CV; Sun Y; Mangala LS; Li X; Ji P; Cogdell D; Hu L; Wang Y; Rodriguez-Aguayo C; Lopez-Berestein G; Shmulevich I; De Cecco L; Chen K; Mezzanzanica D; Xue F; Sood AK; Zhang W
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25995442
[TBL] [Abstract][Full Text] [Related]
48. ADAM12-L is a direct target of the miR-29 and miR-200 families in breast cancer.
Duhachek-Muggy S; Zolkiewska A
BMC Cancer; 2015 Mar; 15():93. PubMed ID: 25886595
[TBL] [Abstract][Full Text] [Related]
49. Sox9 and Hif-2α regulate TUBB3 gene expression and affect ovarian cancer aggressiveness.
Raspaglio G; Petrillo M; Martinelli E; Li Puma DD; Mariani M; De Donato M; Filippetti F; Mozzetti S; Prislei S; Zannoni GF; Scambia G; Ferlini C
Gene; 2014 Jun; 542(2):173-81. PubMed ID: 24661907
[TBL] [Abstract][Full Text] [Related]
50. Regulation of colony stimulating factor-1 expression and ovarian cancer cell behavior in vitro by miR-128 and miR-152.
Woo HH; László CF; Greco S; Chambers SK
Mol Cancer; 2012 Aug; 11():58. PubMed ID: 22909061
[TBL] [Abstract][Full Text] [Related]
51. Epigenetic modification is involved in aberrant expression of class III beta-tubulin, TUBB3, in ovarian cancer cells.
Izutsu N; Maesawa C; Shibazaki M; Oikawa H; Shoji T; Sugiyama T; Masuda T
Int J Oncol; 2008 Jun; 32(6):1227-35. PubMed ID: 18497984
[TBL] [Abstract][Full Text] [Related]
52. Competitive regulation of nucleolin expression by HuR and miR-494.
Tominaga K; Srikantan S; Lee EK; Subaran SS; Martindale JL; Abdelmohsen K; Gorospe M
Mol Cell Biol; 2011 Oct; 31(20):4219-31. PubMed ID: 21859890
[TBL] [Abstract][Full Text] [Related]
53. Involvement of miR-29b signaling in the sensitivity to chemotherapy in patients with ovarian carcinoma.
Dai F; Zhang Y; Chen Y
Hum Pathol; 2014 Jun; 45(6):1285-93. PubMed ID: 24767251
[TBL] [Abstract][Full Text] [Related]
54. Hu antigen R and tristetraprolin: counter-regulators of rat apical sodium-dependent bile acid transporter by way of effects on messenger RNA stability.
Chen F; Shyu AB; Shneider BL
Hepatology; 2011 Oct; 54(4):1371-8. PubMed ID: 21688286
[TBL] [Abstract][Full Text] [Related]
55. MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma.
Ge T; Liu T; Guo L; Chen Z; Lou G
Exp Cell Res; 2020 Nov; 396(1):112241. PubMed ID: 32835657
[TBL] [Abstract][Full Text] [Related]
56. The mRNA stability factor HuR inhibits microRNA-16 targeting of COX-2.
Young LE; Moore AE; Sokol L; Meisner-Kober N; Dixon DA
Mol Cancer Res; 2012 Jan; 10(1):167-80. PubMed ID: 22049153
[TBL] [Abstract][Full Text] [Related]
57. [Expression of microRNA 27a and its correlation with drug resistance in human ovarian cancer A2780/Taxol cells].
Li ZM; Hu S; Xiao L; Wang J; Cai J; Yu LL; Wang ZH
Zhonghua Fu Chan Ke Za Zhi; 2010 May; 45(5):372-5. PubMed ID: 20646448
[TBL] [Abstract][Full Text] [Related]
58. Exosomal miR-200c suppresses chemoresistance of docetaxel in tongue squamous cell carcinoma by suppressing TUBB3 and PPP2R1B.
Cui J; Wang H; Zhang X; Sun X; Zhang J; Ma J
Aging (Albany NY); 2020 Apr; 12(8):6756-6773. PubMed ID: 32310826
[TBL] [Abstract][Full Text] [Related]
59. MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells.
Li N; Yang L; Wang H; Yi T; Jia X; Chen C; Xu P
PLoS One; 2015; 10(6):e0128886. PubMed ID: 26043084
[TBL] [Abstract][Full Text] [Related]
60. HuR and miR-1192 regulate myogenesis by modulating the translation of HMGB1 mRNA.
Dormoy-Raclet V; Cammas A; Celona B; Lian XJ; van der Giessen K; Zivojnovic M; Brunelli S; Riuzzi F; Sorci G; Wilhelm BT; Di Marco S; Donato R; Bianchi ME; Gallouzi IE
Nat Commun; 2013; 4():2388. PubMed ID: 24005720
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
